ARTV Artiva Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817241 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-23.9%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-43.6%
ROA-39.9%
ROIC (approx.)-45.8%
Asset turnover—
Leverage & solvency
Liabilities / assets6.5%
Debt / equity0.00x
Current ratio19.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $0 | $251,000 | $33.49M |
| R&D expense | $69.54M | $50.33M | $50.25M |
| SG&A expense | $20.27M | $17.20M | $13.91M |
| Operating income | -$89.81M | -$67.28M | -$30.67M |
| Pretax income | $83.90M | $65.40M | -$28.65M |
| Income tax | $0 | $0 | $72,000 |
| Net income | -$83.86M | -$65.37M | -$28.72M |
| EBITDA | -$87.21M | -$64.85M | -$28.41M |
| EPS (basic) | -3.43 | -5.81 | -35.78 |
| EPS (diluted) | -3.43 | -5.81 | -35.78 |
| Weighted avg. shares (diluted) | 24.44M | 11.26M | 802,747 |
| Balance sheet | |||
| Cash & equivalents | $26.70M | $40.49M | $53.76M |
| Short-term investments | $81.31M | $145.19M | $23.47M |
| Receivables | — | $0 | $1.03M |
| Current assets | $112.67M | $188.63M | $79.82M |
| PP&E, net | $6.62M | $6.37M | $8.10M |
| Total assets | $130.94M | $209.58M | $105.11M |
| Current liabilities | $13.09M | $12.25M | $12.23M |
| Total liabilities | $20.97M | $22.94M | $50.72M |
| Shareholders' equity | $109.97M | $186.64M | -$162.01M |
| Cash flow statement | |||
| Operating cash flow | -$76.75M | -$55.03M | -$47.43M |
| Capital expenditure | $2.59M | $642,000 | $3.26M |
| Free cash flow | -$79.34M | -$55.67M | -$50.69M |
| Investing cash flow | $63.41M | -$120.46M | -$25.98M |
| Financing cash flow | $9,000 | $162.23M | $24.39M |
| Depreciation & amortization | $2.60M | $2.43M | $2.27M |
| Stock-based compensation | $6.82M | $6.98M | $7.05M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.